Medislim GmbH
- Address
- Bahnhofstrasse 9, 69469 Weinheim, Germany
Cardiovascular Diseases
Research at Medislim GmbH focuses on cardiovascular disease and related conditions such as hypertension, evaluating innovative drug combinations like vicadrostat with empagliflozin to lower the risk of heart failure and cardiovascular death in patients with type 2 diabetes.
- Combination therapy for heart‑failure risk reduction
- Evaluation of cardiovascular outcomes in diabetic patients
- Assessment of blood‑pressure control impact
The site’s multidisciplinary team collaborates to bring new cardiovascular solutions to the Weinheim community.
Immune System Diseases
Clinical studies target the prevention of viral‑induced immune disorders, including a vaccine against herpes zoster (HZ/su) and an mRNA candidate (mRNA‑1647) for primary CMV infection, aiming to demonstrate safety, reactogenicity and long‑term protection.
- Long‑term protection against shingles
- Prevention of primary cytomegalovirus infection
- Safety and reactogenicity of novel mRNA vaccines
Medislim GmbH’s immune‑research program supports the development of next‑generation vaccines for older adults.
Nutritional and Metabolic Diseases
The center conducts trials on weight‑management therapies, testing a once‑weekly agent (MET097) designed to promote weight loss in individuals with obesity and to improve metabolic parameters in those with type 2 diabetes.
- Weekly therapy for body‑weight reduction
- Impact on metabolic health markers
- Integration with diabetes management
These studies aim to provide effective, convenient options for patients struggling with excess weight and metabolic risk.
Respiratory Tract Diseases
Ongoing investigations evaluate a seasonal vaccine (RSVPreF3 OA) against respiratory syncytial virus, measuring the humoral immune response after revaccination in younger adults at risk and comparing it with older adults (≥ 60 years).
- Revaccination strategies for RSV
- Comparison of immune response across age groups
- Safety of seasonal RSV immunization
Medislim GmbH’s respiratory program seeks to reduce the burden of RSV in vulnerable adult populations.
Virus Diseases
A broader viral‑disease portfolio includes vaccine development for several viral infections, such as CMV, RSV and herpes zoster, with the goal of demonstrating efficacy across diverse age groups and improving overall infection prevention.
- Development of mRNA‑based viral vaccines
- Cross‑age efficacy assessments
- Monitoring of infection prevention outcomes
The site’s integrated approach leverages expertise in virology to advance public‑health solutions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Boehringer Ingelheim Espana S.A.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1GlaxoSmithKline Biologicals3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medislim GmbH
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of MET097 in Adults with Overweight or Obesity: A Phase 3, Randomized, Placebo-Controlled Trial | Metsera Inc. | Phase III | Not Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E | 2 | Unknown | 2024-06-04 | 2024-08-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.